Lycorine chlorideCAS# 2188-68-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 2188-68-3 | SDF | Download SDF |
| PubChem ID | 164943 | Appearance | White powder |
| Formula | C16H17NO4Cl | M.Wt | 322.8 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | DMSO : 25 mg/mL (77.22 mM; Need ultrasonic) | ||
| SMILES | C1CN2CC3=CC4=C(C=C3C5C2C1=CC(C5O)O)OCO4.Cl | ||
| Standard InChIKey | VUVNTYCHKZBOMV-NVJKKXITSA-N | ||
| Standard InChI | InChI=1S/C16H17NO4.ClH/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19;/h3-5,11,14-16,18-19H,1-2,6-7H2;1H/t11-,14-,15+,16+;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Lycorine chloride( Lycorine hydrochloride) is a VE-cadherin inhibitor with the IC50 of 1.2μM in Hey1B cell. It selectively inhibited ovarian cancer cell proliferation and neovascularization and is a potential drug candidate for anti-ovarian cancer therapy. |
| Targets | VEGFR | Akt | p21 |
| In vitro | Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry.[Pubmed: 22781316 ]Pigment Cell Melanoma Res, 2012,25(5):630-8.Melanoma cells actively participate in tumor angiogenesis and vasculogenic mimicry. However, anti-angiogenic therapy in patients with melanoma has not shown a significant survival gain. Thus, new anti-melanoma angiogenic and vasculogenic drugs are highly desired.
|
| Cell Research | Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity.[Pubmed: 23376478 ]Toxicol Lett. 2013 Apr 12;218(2):174-85Uncontrolled tumor cell proliferation and robust neovascularization are prominent features of aggressive ovarian cancers. Although great efforts in anti-ovarian cancer therapy have been made in the past 4 decades, the 5-year survival rates for ovarian cancer patients are still poor, and effective drugs to cure ovarian cancer patients are absent.
|
Lycorine chloride Dilution Calculator
Lycorine chloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0979 mL | 15.4895 mL | 30.9789 mL | 61.9579 mL | 77.4473 mL |
| 5 mM | 0.6196 mL | 3.0979 mL | 6.1958 mL | 12.3916 mL | 15.4895 mL |
| 10 mM | 0.3098 mL | 1.5489 mL | 3.0979 mL | 6.1958 mL | 7.7447 mL |
| 50 mM | 0.062 mL | 0.3098 mL | 0.6196 mL | 1.2392 mL | 1.5489 mL |
| 100 mM | 0.031 mL | 0.1549 mL | 0.3098 mL | 0.6196 mL | 0.7745 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Lycorine (hydrochloride) is VE-cadherin inhibitor,and has IC50 of 1.2μM in Hey1B cell. IC50: 1.2μM (Hey1B cell)[2] In vitro:Lycorine (hydrochloride) executed an anti-melanoma vasculogenic effect by inhibiting VE-cadherin gene expression in C8161 cells and caused a decrease in cell surface exposure of VE-cadherin protein. Consistently, LH significantly suppressed VE-cadherin gene promoter activity. [1] Lycorine (hydrochloride) effectively inhibited mitotic proliferation of Hey1B cells (half maximal inhibitory concentration = 1.2 μM) with very low toxicity, resulting in cell cycle arrest at the G2/M transition through enhanced expression of the cell cycle inhibitor p21 and marked down-regulation of cyclin D3 expression. Moreover, LH suppressed both the formation of capillary-like tubes by Hey1B cells cultured in vitro.[2] In vivo: Lycorine effectively suppressed C8161 cell-dominant tumor formation and generation of tumor blood vessels in vivo with low toxicity.[1] Lycorine (hydrochloride) suppressed the formation of the ovarian cancer cell-dominant neovascularization in vivo when administered to Hey1B-xenotransplanted mice, suggest that LH selectively inhibits ovarian cancer cell proliferation and neovascularization and is a potential drug candidate for anti-ovarian cancer therapy.[2]
References:
[1]. Liu, R. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment cell & melanoma research 25, 630-638, doi:10.1111/j.1755-148X.2012.01036.x (2012).
[2]. Cao, Z. et al.Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicology letters 218, 174-185, doi:10.1016/j.toxlet.2013.01.018 (2013).
- Boc-Arg(NO2)-OH
Catalog No.:BCC3065
CAS No.:2188-18-3
- 12-Hydroxyisodrimenin
Catalog No.:BCN4935
CAS No.:218780-16-6
- Boc- ß-HoIle-OH
Catalog No.:BCC3236
CAS No.:218608-82-3
- Bardoxolone methyl
Catalog No.:BCC1400
CAS No.:218600-53-4
- Bardoxolone
Catalog No.:BCC1399
CAS No.:218600-44-3
- Falcarinol
Catalog No.:BCN3938
CAS No.:21852-80-2
- Octahydroisoindole
Catalog No.:BCN2275
CAS No.:21850-12-4
- BDNF (human)
Catalog No.:BCC5944
CAS No.:218441-99-7
- Macrocarpal K
Catalog No.:BCN4934
CAS No.:218290-59-6
- Nifedipine
Catalog No.:BCC4808
CAS No.:21829-25-4
- Vindoline
Catalog No.:BCN4933
CAS No.:2182-14-1
- SRPIN340
Catalog No.:BCC4849
CAS No.:218156-96-8
- Horminone
Catalog No.:BCN4936
CAS No.:21887-01-4
- Boc-Orn-OH
Catalog No.:BCC3427
CAS No.:21887-64-9
- 1-Phenyloctane
Catalog No.:BCN2227
CAS No.:2189-60-8
- Taraxeryl acetate
Catalog No.:BCN4937
CAS No.:2189-80-2
- Ciwujiatone
Catalog No.:BCN7598
CAS No.:218901-26-9
- Euphorbia factor L2
Catalog No.:BCN3783
CAS No.:218916-51-9
- 5,15-Diacetyl-3-benzoyllathyrol
Catalog No.:BCN1196
CAS No.:218916-52-0
- Euphorbia factor L8
Catalog No.:BCN3785
CAS No.:218916-53-1
- KNK437
Catalog No.:BCC6399
CAS No.:218924-25-5
- Z-Trp(Boc)-OH.DCHA
Catalog No.:BCC2749
CAS No.:218938-57-9
- Boc-ß-HoGlu(OBzl)-OH
Catalog No.:BCC3233
CAS No.:218943-30-7
- 2,3-Dihydro-3-methoxywithaferin A
Catalog No.:BCN7943
CAS No.:21902-96-5
